Response to: 'Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: case report' by Bader-Meunier et al

Ann Rheum Dis. 2022 Feb;81(2):e21. doi: 10.1136/annrheumdis-2020-217000. Epub 2020 Feb 13.

¹ Department of Pediatrics, Stanford University, Stanford, California, USA.
² Institute for Immunity, Transplantation and Infection, Center for Biomedical Informatics, Medicine, Stanford University, Stanford, California, USA.
³ Department of Pediatrics, Program in Immunology, Stanford University, Stanford, California, USA mellins@stanford.edu.

No abstract available

Keywords: DMARDs (biologic); inflammation; juvenile idiopathic arthritis.

Publication types